- Pfizer reported Q3 adjusted EPS of $0.87 versus $0.73 expected and revenue of $16.58 billion versus $15.87 billion expected, per LSEG.
- Pfizer now expects FY26 revenue of $62 billion to $64 billion, up from $60.5 billion to $62.5 billion, and adjusted EPS of $2.95 to $3.05, up from $2.80 to $3.00.
- Eliquis sales rose 25% to $2.52 billion in Q3, above the $2.40 billion analyst estimate, and Paxlovid booked $449 million versus $394.1 million expected.
- Cecile Guegan became Pfizer's CFO in November, after serving as interim CFO since August when Dave Denton left for Nike.
- Pfizer targets roughly $9.7 billion in net savings through 2029 under its expanded cost-cutting program.
- Q3 GAAP net income was $3.24 billion, or 56 cents per share, down from $3.54 billion, or 62 cents per share, a year earlier.
Quotes
“strong year-to-date performance”